HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review
Samo za registrovane korisnike
Obradović, Milan M.
Samardžić, Vladimir S.
Tica Jevtic, Jelena
Bajić, Vladimir B.
Isenović, Esma R.
Članak u časopisu (Objavljena verzija)
© 2019 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd.
MetapodaciPrikaz svih podataka o dokumentu
What is known and objective: The HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia. Case description: A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five-point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge. What is new and conclusion: In thalassaemia and haemoglobinopathies, due to discrepancies in the five-point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously. © 2019 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd.
Ključne reči:diabetes / fructosamine / glycaemic control / glycaemic profile / HbA1C / thalassaemia
Izvor:Journal of Clinical Pharmacy and Therapeutics, 2019, 45, 2, 379-383
- Hormonska regulacija ekspresije i aktivnosti azot oksid sintaze i natrijum-kalijumove pumpe u eksperimentalnim modelima insulinske rezistencije, dijabetesa i kardiovaskularnih poremećaja (RS-173033)
- KAUST 
- KAUST Base Research Fund [BAS/1/1606-01-01]
- KAUST Office of Sponsored Research (OSR) [FCC/1/1976-17-01]